Publication | Closed Access

Muraglitazar, a dual (α/γ) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes

Diabetes ManagementPpar ActivatorMedicineDiabetesClinical TrialsType 224-Week Monotherapy TrialPharmacotherapyDiabetes MellitusPharmacology